Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome

Toyohiko Watanabe, Shinya Uehara, Daishi Araki, Miyabi Inoue, Koichi Monden, Takashi Saika, Yasutomo Nasu, Hiromi Kumon, Teruhiko Yokoyama

Research output: Contribution to journalArticle

Abstract

Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25% decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.

Original languageEnglish
Pages (from-to)578-583
Number of pages6
JournalNishinihon Journal of Urology
Volume69
Issue number10
Publication statusPublished - 2007

Fingerprint

Prostatitis
Pelvic Pain
Nerve Growth Factor
Chronic Pain
Biomarkers
Therapeutics
Pain
Physical Examination
History
Enzyme-Linked Immunosorbent Assay
Quality of Life

Keywords

  • Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
  • National Institutes of Health chronic prostatitis symptom index (NIH-CPSI)
  • Nerve growth factor (NGF)

ASJC Scopus subject areas

  • Urology

Cite this

Watanabe, T., Uehara, S., Araki, D., Inoue, M., Monden, K., Saika, T., ... Yokoyama, T. (2007). Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome. Nishinihon Journal of Urology, 69(10), 578-583.

Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome. / Watanabe, Toyohiko; Uehara, Shinya; Araki, Daishi; Inoue, Miyabi; Monden, Koichi; Saika, Takashi; Nasu, Yasutomo; Kumon, Hiromi; Yokoyama, Teruhiko.

In: Nishinihon Journal of Urology, Vol. 69, No. 10, 2007, p. 578-583.

Research output: Contribution to journalArticle

Watanabe, T, Uehara, S, Araki, D, Inoue, M, Monden, K, Saika, T, Nasu, Y, Kumon, H & Yokoyama, T 2007, 'Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome', Nishinihon Journal of Urology, vol. 69, no. 10, pp. 578-583.
Watanabe, Toyohiko ; Uehara, Shinya ; Araki, Daishi ; Inoue, Miyabi ; Monden, Koichi ; Saika, Takashi ; Nasu, Yasutomo ; Kumon, Hiromi ; Yokoyama, Teruhiko. / Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome. In: Nishinihon Journal of Urology. 2007 ; Vol. 69, No. 10. pp. 578-583.
@article{addd9751856341c592a32aeb1de710cf,
title = "Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome",
abstract = "Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25{\%} decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.",
keywords = "Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), Nerve growth factor (NGF)",
author = "Toyohiko Watanabe and Shinya Uehara and Daishi Araki and Miyabi Inoue and Koichi Monden and Takashi Saika and Yasutomo Nasu and Hiromi Kumon and Teruhiko Yokoyama",
year = "2007",
language = "English",
volume = "69",
pages = "578--583",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "10",

}

TY - JOUR

T1 - Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome

AU - Watanabe, Toyohiko

AU - Uehara, Shinya

AU - Araki, Daishi

AU - Inoue, Miyabi

AU - Monden, Koichi

AU - Saika, Takashi

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Yokoyama, Teruhiko

PY - 2007

Y1 - 2007

N2 - Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25% decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.

AB - Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25% decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.

KW - Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

KW - National Institutes of Health chronic prostatitis symptom index (NIH-CPSI)

KW - Nerve growth factor (NGF)

UR - http://www.scopus.com/inward/record.url?scp=35948967597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948967597&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 578

EP - 583

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 10

ER -